Masuo Nakai

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Mitsue Mori2
Yutaka Yoshimitsu1
Kimiko Shintaku1
2Mitsue Mori
1Yutaka Yoshimitsu
1Kimiko Shintaku
Learn More
BACKGROUND Regorafenib and its metabolites may inhibit the activities of several CYP or UDP-glucuronosyltransferase isoforms, including that of CYP2C9. Therefore, pharmacological agents that are CYP2C9 substrates may show elevated circulating levels and enhanced drug efficacy when concurrently used with regorafenib. Previous studies showed that the area(More)
We previously proposed two predictive equations of visceral fat area applicable in a field setting (Demura & Sato, 2007a, 2007b). One uses the fat mass of the trunk measured by bioelectrical impedance as the main predictor (equation 1) and the other uses internal fat mass estimated from several anthropometric variables (equation 2). In this study, we(More)
A 40-year-old female with familial adenomatous polyposis (FAP) had a subtotal colectomy at 16 years of age. At 39 years, she had low anterior resection due to advanced rectal carcinoma. Thereafter, we administrated per os uracil and tegafur for 9 months. Metastatic rectal carcinoma was detected in the liver (S8) by computed tomography (CT).(More)
  • 1